MARY LYNN BRESLIN: Open Payments
NPI 1205543774 · NEPTUNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,518 in 78 payments from 22 companies in 2025. Trend: 2023 $988 · 2024 $1,983 · 2025 $1,518
Food & beverage: $1,518
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 14 | $213 |
| GlaxoSmithKline, LLC. | 13 | $207 |
| Gilead Sciences, Inc. | 2 | $142 |
| TAIHO ONCOLOGY, INC. | 6 | $119 |
| ABBVIE INC. | 5 | $103 |
| Stemline Therapeutics Inc. | 5 | $93 |
| E.R. Squibb & Sons, L.L.C. | 5 | $84 |
| Novocure Inc. | 1 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| Pharmacosmos Therapeutics Inc. | 3 | $55 |
Products named: Lenvima, OJJAARA, Trodelvy, LONSURF, Orserdu, VENCLEXTA, Optune Lua (NovoTTF-200T), Enhertu.
Industry payments across NJ — which companies pay providers there.
